Asia-Pacific

After a surge in interest around the covid-19 pandemic, it has been a mixed picture for life sciences and biotech-focused PE fundraising and capital deployment.

EQT Private Capital Asia returned $14bn to investors in 2025 alone, deputy co-head of private capital Asia Hari Gopalakrishnan tells PEI.

Institutions including the International Finance Corporation and British International Investment are prioritising selective manager-led allocations, growth equity and realistic paths to returns.

In today's edition, Why private markets shouldn't shy away from 'cockroach' claims; PE shops may face more AI upsets than their private credit peers; Debt firms could become more selective with their sponsor lending.

CEO Raphael Arndt says the Australian sovereign wealth fund would ‘make changes where it is prudent to do so’ as it manages costs.

Some evergreens enjoy short-term performance boosts from secondaries mark-ups, JPMorgan Asset Management portfolio manager Brian Lam tells Private Equity International.

Nearly half of the private equity funds that closed in the first quarter met their fundraising targets – the highest proportion in at least five years.

In today's edition, PE's liquidity crunch is driving an evolution in structured offerings; AI's defence drive could create headaches for tech investors; Tikehau targets Japan.

The benefits and challenges of the past 12 months makes for a mixed picture for GP stakes as 2026 takes shape.